Publication dates

All regions

Pancreatic Cancer Industry, November 2014 Market Reports from Top Publishers

You might be interested in: Cancer, Therapeutics, Melanoma, more »


 
1-20 of about 8 400 reports for Pancreatic Cancer

Green Cross Cell Corporation (031390) - Financial and Strategic SWOT Analysis Review

Green Cross Cell Corporation (031390) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Of liver cancer. Green cross also conducts phase iii clinical studies on liver cancer and brain tumors; and investigative clinical studies on pancreatic cancer, as well as has completed various pre ...

AB Science (Symbol:AB) SWOT Analysis, Strategy, Revenues and Profits

AB Science (Symbol:AB) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... New predictive markers for pancreatic cancer survival associated with masitinib treatmentthis comprehensive swot profile of ab science provides you an in-depth strategic analysis of the company ...

Acuvax Ltd (Symbol:ACU) SWOT Analysis, Strategy, Revenues and Profits

Acuvax Ltd (Symbol:ACU) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Of products that address west nile virus, pancreatic cancer, dengue, influenza and tick borne encephalitis diseases. Acuvax product consists of vaccines, chemo resistance drugs and medical nutritional ...

Aposense Ltd. (Symbol:APOS) SWOT Analysis, Strategy, Revenues and Profits

Aposense Ltd. (Symbol:APOS) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Include att-11t, att-gem and att-ld. Aposense's att-gem is an oral pro-drug analog of gemcitabine, which is used to treat pancreatic cancer; and att-ld is a pro-drug of levodopa for the treatment ...

Cancer Research UK SWOT Analysis, Strategy, Revenues and Profits

Cancer Research UK SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Cancer treatmentsaug 05, 2014: queen's university scientists boost for cancer prevention researchaug 04, 2014: new trick for old' drug brings hope for pancreatic cancer patients ...

IsoRay, Inc. (Symbol:ISR) SWOT Analysis, Strategy, Revenues and Profits

IsoRay, Inc. (Symbol:ISR) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Esophageal and pancreatic cancer. The organization treats pediatric patient's tumor by utilizing multiple cesium-131 sutured seed meshes for internal radiation therapy. Isoray is headquartered in richland ...

Nuvilex, Inc. (Symbol:NVLX) SWOT Analysis, Strategy, Revenues and Profits

Nuvilex, Inc. (Symbol:NVLX) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Product such as gemzar, tarceva, abraxane, folfirinox, ifex, uromitexan, mesnex and cytoxan. The company's gemzar is a single agent for the treatment of advanced pancreatic cancer; tarceva is a therapy ...

Sunshine Biopharma, Inc. (Symbol:SBFM) SWOT Analysis, Strategy, Revenues and Profits

Sunshine Biopharma, Inc. (Symbol:SBFM) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Different types of multidrug resistant cancer cell lines including breast cancer, uterine carcinoma, pancreatic cancer and small-cell lung cancer. Sunshine biopharma also offers difluoro-etoposide, which ...

Tikcro Technologies, Ltd. (Symbol:TIKRF) SWOT Analysis, Strategy, Revenues and Profits

Tikcro Technologies, Ltd. (Symbol:TIKRF) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Phase ii/b clinical trials for the treatment of pancreatic cancer and for superficial bladder carcinoma cancer, as well as a phase i/iia clinical trial for the treatment of ovarian cancer. Tikcro ...

PharmaEngine, Inc. (4162) - Financial and Strategic SWOT Analysis Review

PharmaEngine, Inc. (4162) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Pharmaengine's product pep02 is for the treatment of metastatic pancreatic cancer. The company is partnered with merrimack pharmaceuticals, inc., And nanobiotix s.A. It has research and development ...

About 600 reports for Pancreatic Cancer

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the US

  • January 2013
    64 pages
  • Cancer  

  • United States  

    North America  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.